Adalimumab-ryvk (subcutaneous route)

Simlandi

Adalimumab-ryvk injection is used to treat the symptoms and prevent the progression of moderate to severe rheumatoid arthritis. It is used in children 2 years of age and older to treat moderate to severe polyarticular juvenile idiopathic arthritis. This medicine is also used to treat psoriatic arthritis, which is a type of arthritis that causes pain and swelling in the joints along with patches of scaly skin on some areas of the body. Adalimumab-ryvk may be used alone or in combination with other medicines (eg, methotrexate). Adalimumab-ryvk injection is also used to treat moderate to severe Crohn's disease, ulcerative colitis, and active ankylosing spondylitis. Adalimumab-ryvk injection is also used to treat moderate to severe chronic plaque psoriasis, which is a skin disease with red patches and white scales that do not go away. It is also used to treat moderate to severe hidradenitis suppurativa, a chronic skin disease that causes small, painful lumps under the skin. This medicine is also used to treat non-infectious uveitis. This product is available in the following dosage forms:

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered: Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of adalimumab-ryvk injection for thetreatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and olderor for thetreatment of Crohn's disease in children 6 years of age and older. However, safety and efficacy have not been established in children younger than 2 years of age for polyarticular juvenile idiopathic arthritis, in children younger than 6 years of age for Crohn's disease, and in children for other conditions. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of adalimumab-ryvk injection in the elderly. However, this medicine may cause serious infections and cancer more often in the elderly, which may require caution in patients receiving this medicine. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially: